JP2014519487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519487A5 JP2014519487A5 JP2014508569A JP2014508569A JP2014519487A5 JP 2014519487 A5 JP2014519487 A5 JP 2014519487A5 JP 2014508569 A JP2014508569 A JP 2014508569A JP 2014508569 A JP2014508569 A JP 2014508569A JP 2014519487 A5 JP2014519487 A5 JP 2014519487A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- interferon
- expression level
- ism
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479314P | 2011-04-26 | 2011-04-26 | |
| US61/479,314 | 2011-04-26 | ||
| US201161582179P | 2011-12-30 | 2011-12-30 | |
| US61/582,179 | 2011-12-30 | ||
| PCT/US2012/035313 WO2012149228A1 (en) | 2011-04-26 | 2012-04-26 | Compositions and method for treating autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519487A JP2014519487A (ja) | 2014-08-14 |
| JP2014519487A5 true JP2014519487A5 (https=) | 2015-06-18 |
| JP6211513B2 JP6211513B2 (ja) | 2017-10-11 |
Family
ID=47072761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508569A Expired - Fee Related JP6211513B2 (ja) | 2011-04-26 | 2012-04-26 | 自己免疫疾患の治療のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140056889A1 (https=) |
| EP (1) | EP2701742A4 (https=) |
| JP (1) | JP6211513B2 (https=) |
| KR (1) | KR20140048877A (https=) |
| AR (1) | AR086074A1 (https=) |
| AU (1) | AU2012249601A1 (https=) |
| CA (1) | CA2834203A1 (https=) |
| WO (1) | WO2012149228A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080057503A1 (en) | 2006-04-24 | 2008-03-06 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| BR112013030242A2 (pt) * | 2011-05-25 | 2016-12-06 | Medimmune Llc | método de tratamento de um distúrbio autoimune em um sujeito humano |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| ES3055223T3 (en) | 2012-05-03 | 2026-02-10 | Alcon Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| MX368903B (es) | 2013-02-20 | 2019-10-21 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| GB201501613D0 (en) * | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| AU2017231833B2 (en) | 2016-03-10 | 2024-03-14 | Viela Bio, Inc. | ILT7 binding molecules and methods of using the same |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018136625A2 (en) * | 2017-01-20 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss |
| US12486320B1 (en) * | 2018-01-15 | 2025-12-02 | Washington University | Compositions and methods for treatment of central nervous system (CNS) autoimmune associated diseases or disorders |
| US11769592B1 (en) | 2018-10-07 | 2023-09-26 | Cerner Innovation, Inc. | Classifier apparatus with decision support tool |
| US11749404B1 (en) * | 2018-10-08 | 2023-09-05 | Cerner Innovation, Inc. | Decision support tool for venous thromboembolism (VTE) |
| JP2022512796A (ja) * | 2018-10-26 | 2022-02-07 | ヤンセン バイオテツク，インコーポレーテツド | Ｉ型インターフェロンシグネチャー及び使用方法 |
| KR102308865B1 (ko) * | 2019-02-08 | 2021-10-05 | 서울대학교산학협력단 | 전신 홍반 루푸스 산모의 임신 위험도를 평가하는 방법 |
| JP7494416B2 (ja) * | 2019-10-31 | 2024-06-04 | 義知 本田 | 血管老化予測方法、疾患リスク予測方法、血管老化予測用バイオマーカー、疾患用バイオマーカー、測定キット、及び、診断装置 |
| IL293572A (en) * | 2019-12-06 | 2022-08-01 | Viela Bio Inc | Treatment methods using ilt7 binding proteins |
| CN114836534A (zh) * | 2021-06-08 | 2022-08-02 | 中国医学科学院北京协和医院 | Samd9l基因突变作为i型干扰素病诊断的标志物及其应用 |
| CN121586729A (zh) * | 2023-05-02 | 2026-02-27 | 4E治疗公司 | 组合物、方法及用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| CN101155831B (zh) * | 2005-02-10 | 2015-08-19 | 贝勒研究院 | 抗干扰素α单克隆抗体及其使用方法 |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US20080057503A1 (en) * | 2006-04-24 | 2008-03-06 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| EP2712930A3 (en) * | 2006-12-06 | 2014-04-23 | MedImmune, LLC | Interferon alpha-induced pharmacodynamic markers |
| CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| CA2772921A1 (en) * | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
-
2012
- 2012-04-26 KR KR1020137031178A patent/KR20140048877A/ko not_active Withdrawn
- 2012-04-26 AU AU2012249601A patent/AU2012249601A1/en not_active Abandoned
- 2012-04-26 WO PCT/US2012/035313 patent/WO2012149228A1/en not_active Ceased
- 2012-04-26 CA CA2834203A patent/CA2834203A1/en not_active Abandoned
- 2012-04-26 AR ARP120101446A patent/AR086074A1/es unknown
- 2012-04-26 EP EP12777107.9A patent/EP2701742A4/en not_active Withdrawn
- 2012-04-26 US US14/113,575 patent/US20140056889A1/en not_active Abandoned
- 2012-04-26 JP JP2014508569A patent/JP6211513B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519487A5 (https=) | ||
| JP2011511804A5 (https=) | ||
| JP2021525236A5 (https=) | ||
| JP2010526107A5 (https=) | ||
| JP2019503167A5 (https=) | ||
| Farci et al. | Current and future management of chronic hepatitis D | |
| JP2017079785A5 (https=) | ||
| JP2019528285A5 (https=) | ||
| Mobini et al. | Computational design of a novel VLP-based vaccine for hepatitis B virus | |
| CN113354733B (zh) | 一种抗SARS-CoV-2流行突变株的单克隆抗体20D8 | |
| CN103396494B (zh) | 一种凝血因子ix的单克隆抗体 | |
| JP2022512796A5 (https=) | ||
| JP2019521647A5 (https=) | ||
| JP2023505492A5 (https=) | ||
| Terryn et al. | Post-exposure treatment with anti-rabies VHH and vaccine significantly improves protection of mice from lethal rabies infection | |
| Stenger et al. | Immune tolerance strategies in siblings with infantile Pompe disease—Advantages for a preemptive approach to high-sustained antibody titers | |
| Bahramali et al. | Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients | |
| Alfaresi et al. | Hepatitis B virus genotypes and precore and core mutants in UAE patients | |
| JP2024116343A (ja) | ヘパピティスｂウイルス複製およびヘパピティスｂウイルス表面抗原分泌の抑制方法 | |
| CA3183611A1 (en) | Treatment of cardiometabolic disease | |
| Zhang et al. | The platelet derived growth factor-B polymorphism is associated with risk of severe fever with thrombocytopenia syndrome in Chinese individuals | |
| Baghi et al. | Impact of the IL-10 promoter gene polymorphisms in the severity of chronic hepatitis B infection | |
| JP2022527542A5 (https=) | ||
| Grzegorzewska et al. | IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection | |
| Barmania et al. | Genetic associations with coronavirus susceptibility and disease severity |